Bratton Larry D, Auerbach Bruce, Choi Chulho, Dillon Lisa, Hanselman Jeffrey C, Larsen Scott D, Lu Gina, Olsen Karl, Pfefferkorn Jeffrey A, Robertson Andrew, Sekerke Catherine, Trivedi Bharat K, Unangst Paul C
Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI 48105, USA.
Bioorg Med Chem. 2007 Aug 15;15(16):5576-89. doi: 10.1016/j.bmc.2007.05.031. Epub 2007 May 17.
In an effort to identify hepatoselective inhibitors of HMG-CoA reductase, two series of pyrroles were synthesized and evaluated. Efforts were made to modify (3R,5R)-7-[3-(4-fluorophenyl)-1-isopropyl-4-phenyl-5-phenylcarbamoyl-1H-pyrrol-2-yl]-3,5-dihydroxy-heptanoic acid sodium salt 30 in order to reduce its lipophilicity and therefore increase hepatoselectivity. Two strategies that were explored were replacement of the lipophilic 3-phenyl substituent with either a polar function (pyridyl series) or with lower alkyl substituents (lower alkyl series) and attachment of additional polar moieties at the 2-position of the pyrrole ring. One compound was identified to be both highly hepatoselective and active in vivo. We report the discovery, synthesis, and optimization of substituted pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase for reducing low density lipoprotein cholesterol (LDL-c) in the treatment of hypercholesterolemia.
为了鉴定HMG-CoA还原酶的肝选择性抑制剂,合成并评估了两个系列的吡咯。人们努力对(3R,5R)-7-[3-(4-氟苯基)-1-异丙基-4-苯基-5-苯基氨基甲酰基-1H-吡咯-2-基]-3,5-二羟基庚酸钠盐30进行修饰,以降低其亲脂性,从而提高肝选择性。探索的两种策略是用极性官能团(吡啶基系列)或低级烷基取代基(低级烷基系列)取代亲脂性的3-苯基取代基,并在吡咯环的2-位连接额外的极性部分。鉴定出一种化合物在体内具有高度肝选择性且具有活性。我们报告了基于取代吡咯的肝选择性配体作为HMG-CoA还原酶的有效抑制剂的发现、合成和优化,用于在高胆固醇血症治疗中降低低密度脂蛋白胆固醇(LDL-c)。